Why is Bharat Immunolog falling/rising?

As of 16-Sep, Bharat Immunological & Biological Corporation Ltd is currently priced at 22.13, reflecting an increase of 0.16 or 0.73%. The stock has shown a trend reversal, gaining after two consecutive days of decline, and has outperformed its sector by 0.45%. However, despite this short-term uptick, the stock has underperformed against the benchmark Sensex over various periods, including a 1-year return of -24.70% compared to the Sensex's -0.73%. Additionally, the stock's delivery volume has decreased by 13.26% against the 5-day average, indicating falling investor participation. The company's long-term fundamentals are weak, with net sales declining at an annual rate of -24.67% and a high debt-to-EBITDA ratio, which raises concerns about its ability to service debt.
In the broader market context, the stock's short-term performance of +0.91% over the past week is less than the Sensex's +1.58%, highlighting a consistent underperformance against the benchmark. The company's lack of declared results in the last six months and negative financial indicators, such as an operating cash flow of INR 0 MM and a high debt-equity ratio, contribute to its perception as a risky investment. Overall, while there is a slight upward movement in the stock price, the underlying fundamentals and market conditions suggest that the stock remains under pressure and may not sustain this momentum in the long term.